8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 13, 2026·SEC
Cue Biopharma, Inc.(CUE)Earnings, Financials & Key Ratios
CUE•NASDAQ
$33.39
Price updated Jul 7, 2026
AboutCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$27M+195.7%
- EBITDA-$23M+41.1%
- Net Income-$27M+34.6%
- EPS (Diluted)-8.40+61.1%
- Gross Margin100%
- EBITDA Margin-83.89%+80.1%
- Operating Margin-96.56%+78.4%
- Net Margin-96.85%+77.9%
- ROE-121.11%+18.7%
CUE Price & Volume
Cue Biopharma, Inc. (CUE) stock price & volume — 10-year historical chart
Loading chart...
Volatile Milestone Revenue Masks Persistent Burn Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and dilution
Key Thesis Takeaways
- Cue Biopharma faces a precarious outlook defined by a reliance on sporadic milestone payments, which caused revenue to fluctuate wildly from $0.4M to $21.9M over the last ten quarters.
- The company's inability to achieve consistent operating leverage, evidenced by persistent quarterly R&D spending often exceeding $7M, necessitates frequent capital raises to sustain its clinical pipeline.
- Investors should remain cautious as the rapid erosion of the cash position from $48.5M in 2023Q4 to $16.4M in 2026Q1 suggests significant dilution risk remains on the horizon.
Verdict Logic
the company's liquidity buffer is rapidly depleting, with cash reserves falling to $16.4M in 2026Q1, which likely necessitates further dilutive equity financing to support ongoing operations.
CUE Growth Metrics
Cue Biopharma, Inc. (CUE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years54.16%
3 Years180.46%
TTM309.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM51.89%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM72.5%
Return on Capital
10 Years-79.93%
5 Years-91.16%
3 Years-109.39%
Last Year-112.33%
Peers Comparison
Key metrics vs top competitors for Cue Biopharma, Inc. (CUE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.39 | $87.75M | -3.98 | 195.75% | -96.85% | -121.11% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Compare CUE vs Peers
Cue Biopharma, Inc. (CUE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CUE SEC Filings & Documents
Cue Biopharma, Inc. (CUE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CUE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CUE Frequently Asked Questions
Cue Biopharma, Inc. (CUE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cue Biopharma, Inc.'s revenue?
Cue Biopharma, Inc. (CUE) reported $32.7M in revenue for fiscal year 2025.
How fast is Cue Biopharma, Inc. growing?
Cue Biopharma, Inc. (CUE) grew revenue by 195.7% over the past year. This is strong growth.
Is CUE profitable?
Cue Biopharma, Inc. (CUE) reported a net loss of $19.5M for fiscal year 2025.
Dividend & Returns
What is CUE's return on equity?
Cue Biopharma, Inc. (CUE) has a return on equity (ROE) of -121.1%. Negative ROE indicates the company is unprofitable.
What is Cue Biopharma, Inc.'s free cash flow?
Cue Biopharma, Inc. (CUE) had negative free cash flow of $24.6M in fiscal year 2025, likely due to heavy capital investments.